Fujifilm Of Japan Bets Generics At Home Will Drive Medicine Emphasis
This article was originally published in PharmAsia News
Executive SummaryJapan's Fujifilm Holdings is betting on its nation becoming a major market for generic drugs by using a subsidiary less than a month old to develop the medicines
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.